A detailed history of Signaturefd, LLC transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 5,034 shares of ITOS stock, worth $36,848. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,034
Previous 5,147 2.2%
Holding current value
$36,848
Previous $76,000 32.89%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024

SELL
$10.09 - $17.97 $1,140 - $2,030
-113 Reduced 2.2%
5,034 $51,000
Q2 2024

Jul 29, 2024

SELL
$10.33 - $18.09 $1,053 - $1,845
-102 Reduced 1.94%
5,147 $76,000
Q1 2024

May 03, 2024

BUY
$9.89 - $13.64 $7,595 - $10,475
768 Added 17.14%
5,249 $71,000
Q4 2023

Jan 31, 2024

BUY
$8.57 - $11.06 $27,981 - $36,110
3,265 Added 268.5%
4,481 $49,000
Q3 2023

Nov 03, 2023

BUY
$10.95 - $14.6 $602 - $803
55 Added 4.74%
1,216 $13,000
Q2 2023

Aug 01, 2023

BUY
$12.93 - $18.05 $11,236 - $15,685
869 Added 297.6%
1,161 $15,000
Q1 2023

Apr 28, 2023

BUY
$13.02 - $22.62 $2,018 - $3,506
155 Added 113.14%
292 $3,000
Q4 2022

Jan 27, 2023

SELL
$17.77 - $21.6 $799 - $972
-45 Reduced 24.73%
137 $2,000
Q3 2022

Nov 08, 2022

BUY
$18.6 - $27.25 $3,124 - $4,578
168 Added 1200.0%
182 $3,000
Q2 2022

Aug 10, 2022

BUY
$16.57 - $35.1 $231 - $491
14 New
14 $0
Q1 2022

May 02, 2022

SELL
$31.92 - $47.45 $159 - $237
-5 Closed
0 $0
Q4 2021

Jan 25, 2022

BUY
$26.23 - $47.86 $131 - $239
5 New
5 $0
Q3 2021

Oct 28, 2021

SELL
$23.91 - $29.58 $717 - $887
-30 Closed
0 $0
Q2 2021

Jul 26, 2021

BUY
$17.9 - $36.1 $537 - $1,083
30 New
30 $1,000

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $260M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Signaturefd, LLC Portfolio

Follow Signaturefd, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.